Royalty Pharma plc (RPRX)

Market Cap	20.66B
Revenue (ttm)	2.31B
Net Income (ttm)	1.02B
Shares Out	583.17M
EPS (ttm)	2.32
PE Ratio	15.24
Forward PE	7.14
Dividend	$0.88 (2.48%)
Ex-Dividend Date	Aug 15, 2025

Volume	4,000,490
Open	35.10
Previous Close	35.15
Day's Range	35.05 - 35.65
52-Week Range	24.05 - 38.00
Beta	0.57
Analysts	Strong Buy
Price Target	45.33 (+27.98%)
Earnings Date	Nov 5, 2025

About RPRX

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 16, 2020
• Employees: 99
• Stock Exchange: NASDAQ
• Ticker Symbol: RPRX
• Website: https://www.royaltypharma.com

Financial Performance

In 2024, Royalty Pharma's revenue was $2.26 billion, a decrease of -3.86% compared to the previous year's $2.35 billion. Earnings were $858.98 million, a decrease of -24.31%.

Analyst Summary

According to 3 analysts, the average rating for RPRX stock is "Strong Buy." The 12-month stock price target is $45.33, which is an increase of 27.98% from the latest price.

Price Target

$45.33

(27.98% upside)

Analyst Consensus: Strong Buy